Characteristics of clinical phenotypes of atopic dermatitis in pregnant women

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Background: Genotypes, phenotypes, and endotypes of atopic dermatitis (AD) are currently being actively studied. It is known that AD endotypes depend on the presence of mutations in the filaggrin gene (FLG). However, determining the blood FLG level seems promising due to the availability of the enzyme-linked immunosorbent assay (ELISA) method and the relatively low cost of the study compared to identifying genetic mutations in FLG. Interleukin-33 (IL-33) is produced in large quantities in keratinocytes of patients with AD. IL-33 induces the expression of IL-31, thereby promoting itching and scratching, as well as aggravating the dysfunction of the skin barrier in AD. AD in pregnancy is a poorly studied issue, which explains the relevance of the study.

Objective: Determination of the clinical AD phenotypes and the blood FLG, IL-31 and IL-33 protein levels during pregnancy.

Materials and methods: The object of the study was 70 pregnant women with an exacerbation of AD. Clinical examination included a history of the disease and an assessment of the severity using the SCORAD index. The level of FLG, IL-31 and IL-33 was determined by ELISA in the blood serum. Statistical analysis was performed using IBM SPSS Statistics 23.

Results and discussion: Based on the SCORAD index results and anamnesis data, four phenotypes of AD during pregnancy were identified. The FLG level was higher in the phenotype characterized by a severe course and ineffectiveness of topical therapy. The IL-33 level did not have statistically significant differences between the AD phenotypes, but the IL-31 level was statistically significantly different (p < 0.05).

Conclusion: The most common clinical phenotypes of AD during pregnancy are isolated AtD and AtD in combination with other allergopathology. The blood FLG level is highest in the AD phenotype with a severe course and resistance to topical therapy. The concentration of IL-31 is important for the diagnosis of AD phenotypes.

Texto integral

Acesso é fechado

Sobre autores

Yulia Kandrashkina

Penza State University

Email: novikova10l@mail.ru
ORCID ID: 0000-0002-5537-5729

Cand. Sci. (Med.), Associate Professor, Department of Obstetrics and Gynecology

Rússia, Penza

Ekaterina Orlova

Penza Institute for Advanced Medical Training – Branch of the RMACPE

Autor responsável pela correspondência
Email: lisaorl@yandex.ru
ORCID ID: 0000-0002-3902-2018

Dr. Sci. (Med.), Associate Professor, Head of the Department of Allergology and Immunology with a Course in Dermatovenereology and Cosmetology

Rússia, Penza

Bibliografia

  1. Eichenfield L.F., Stripling S., Fung S., et al. Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting. Paediatr Drugs. 2022;24(4):293–305. https://dx.doi.org/10.1007/s40272-022-00499-x
  2. Монахов К.Н., Домбровская Д.К., Назаренко Э.В. Применение пробиотиков с Lactobacillus rhamnosus GG в профилактике атопического дерматита у детей. Фарматека. 2017;1:61–65. [Monakhov K.N., Dombrovskaya D.K., Nazarenko E.V. Use of probiotics with Lactobacillus rhamnosus GG in the prevention of atopic dermatitis in children. Farmateka. 2017;1:61–65. (In Russ.)]. URL: https://pharmateca.ru/ru/archive/article/34385
  3. Холодилова Н.А., Монахова К.Н. Влияние приема синбиотика во время беременности на развитие атопического дерматита у детей. Фарматека. 2022;8:81–84. [Kholodilova N.A., Monakhova K.N. The effect of synbiotic intake during pregnancy on the development of atopic dermatitis in children. Farmateka. 2022;8:81–84. (In Russ.)]. https://dx.doi.org/10.18565/pharmateca.2022.8.81-84
  4. Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012;67:1475–1482. https://dx.doi.org/10.1111/all.12049
  5. Cabanillas B., Brehler A.C., Novak N. Atopic dermatitis phe-notypes and the need for personalized medicine. Curr Opin Allergy Clin Immunol. 2017;17(4):309–315. https://dx.doi.org/10.1097/ACI.0000000000000376
  6. Елисютина О.Г., Литовкина А.О., Смольников Е.В. и др. Клинические особенности различных фенотипов атопического дерматита. Российский аллергологический журнал. 2019;16(4):30–41. [Elisyutina O.G., Litovkina A.O., Smol’nikov E.V., et al. Clinical features of various phenotypes of atopic dermatitis. Rossijskij Allergologicheskij Zhurnal. 2019;16(4):30–41. (In Russ.)]. https://dx.doi.org/10.36691/RAJ.2020.16.4.004
  7. Osawa R., Akiyama M., Shimizu H. Filaggrin gene defects and the risk of developing allergic disorders. Allergol Int. 2011;60(1):1–9. https://dx.doi.org/10.2332/allergolint.10-RAI-0270
  8. Zhang H., Guo Y., Wang W., et al. Mutations in the filaggrin gene in Han Chinese patients with atopic dermatitis. Allergy. 2011;66(3):420–427. https://dx.doi.org/10.1111/j.1398-9995.2010.02493.x
  9. Landeck L., Visser M., Kezic S., et al. Genotype-phenotype associations in filaggrin loss-of-function mutation carriers. Contact Dermatitis. 2013;68(3):149–155. https://dx.doi.org/10.1111/j.1600-0536.2012.02171.x
  10. Тамразова О.Б., Глухова Е.А. Уникальная молекула филаггрин в структуре эпидермиса и ее роль в развитии ксероза и патогенеза атопического дерматита. Клиническая дерматология и венерология. 2021;20(6):102–110. [Tamrazova O.B., Glukhova E.A. Unique molecule filaggrin in epidermal structure and its role in the xerosis development and atopic dermatitis pathogenesis. Russian Journal of Clinical Dermatology and Venereology. 2021;20(6):102–110. (In Russ.)]. https://dx.doi.org/10.17116/klinderma202120061102
  11. Rasheed Z., Zedan K., Saif G.B., et al. Markers of atopic dermatitis, allergic rhinitis and bronchial asthma in pediatric patients: correlation with filaggrin, eosinophil major basic protein and immunoglobulin E. Clin Mol Allergy. 2018;16:23. https://dx.doi.org/10.1186/s12948-018-0102-y
  12. Ghada A., Rasheed Z, Salama R.H., et al. Filaggrin, major basic protein and leukotriene B4: Biomarkers for adult patients of bronchial asthma, atopic dermatitis and allergic rhinitis. Intractable Rare Dis Res. 2018;7(4):264–270. https://dx.doi.org/10.5582/irdr.2018.01111
  13. Кандрашкина Ю.А., Орлова Е.А., Левашова О.А. и др. Филаггрин как маркер обострения атопического дерматита при беременности. Фарматека. 2024;31(1–2):183–187. [Kandrashkina Yu.A., Orlova E.A., Levashova O.A., et al. Filaggrin as a marker of exacerbation of atopic dermatitis during pregnancy. Farmateka. 2024;31(1–2):183–187. (In Russ.)]. https://dx.doi.org/10.18565/pharmateca.2024.1.183-187
  14. Proksch E. pH in nature, humans and skin. J Dermatol. 2018;45(9):1044–1052. https://dx.doi.org/10.1111/1346-8138.14489
  15. Kobiela A., Hovhannisyan L., Jurkowska P., et al. Excess filaggrin in keratinocytes is removed by extracellular vesicles to prevent premature death and this mechanism can be hijacked by Staphylococcus aureus in a TLR2–dependent fashion. J Extracell Vesicles. 2023;12(6):e12335. https://dx.doi.org/10.1002/jev2.12335
  16. Presland R.B., Kuechle M.K., Lewis S.P., et al. Regulated expression of human filaggrin in keratinocytes results in cytoskeletal disruption, loss of cell-cell adhesion, and cell cycle arrest. Exp Cell Res. 2001;270(2):199213. https://dx.doi.org/10.1006/excr.2001.5348
  17. Imai Y. Interleukin-33 in atopic dermatitis. J Dermatol Sci. 2019;96(1):2–7. https://dx.doi.org/10.1016/j.jdermsci.2019.08.006
  18. Клинические рекомендации по атопическому дерматиту. Российская ассоциация аллергологов и клинических иммунологов, союз педиатров России, Национальный альянс дерматовенерологов и косметологов, 2023. 119 с. [Clinical guidelines for atopic dermatitis. Russian Association of Allergists and Clinical Immunologists, Union of Pediatricians of Russia, National Alliance of Dermatovenerologists and Cosmetologists, 2023. 119 p. (In Russ.)]. URL: https://raaci.ru/dat/pdf/KR/atopic_dermatitis_2020.pdf
  19. Кандрашкина Ю.А., Орлова Е.А. Увлажняющая и противозудная дермокосметика в лечении атопического дерматита при беременности. Фарматека.2025;32(3):129–133. [Kandrashkina Yu.A., Orlova E.A. Moisturizing and antipruritic dermocosmetics in the treatment of atopic dermatitis during pregnancy. Farmateka.2025;32(3):129–133. (In Russ.)]. https://dx.doi.org/10.18565/pharmateca.2025.3.129-133
  20. Монахов К.Н., Холодилова Н.А. Особенности ведения пациенток с обострением атопического дерматита на фоне беременности. Фарматека. 2018;1:47–51. [Monakhov K.N., Kholodilova N.A. Peculiarities of management of patients with exacerbation of atopic dermatitis during pregnancy. Farmateka. 2018;1:47–51. (In Russ.)]. https://dx.doi.org/10.18565/pharmateca.2018.s1.47-51

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar
2. Figure 1. Serum filaggrin level, ng/ml

Baixar (43KB)
Metadados
3. Figure 2. Serum IL-31 and IL-33 level, pg/ml

Baixar (56KB)
Metadados

Declaração de direitos autorais © Bionika Media, 2025